Biomarkers (2)
- HGB - Hemoglobin (phv00302068.v2.p1)
- HGB - Hemoglobin (phv00482753.v1.p1)
Demographics (2)
- AGE_TREATMENT - Age at time of treatment (phv00482729.v1.p1)
- SEX - Sex of participant (phv00482725.v1.p1)
Disease Events (5)
- AFFECTION_STATUS - Case control status of the subject for lymphoma (phv00482745.v1.p1)
- AFFECTION_STATUS - Case control status of the subject for lymphoma (phv00482726.v1.p1)
- AFFECTION_STATUS - Case control status of the subject for lymphoma (phv00482756.v1.p1)
- AGE_AT_Dx - Age at diagnosis (phv00482748.v1.p1)
- AGE_AT_DX - Age at diagnosis (phv00302063.v2.p1)
Race and Ethnicity (5)
- ETHNICITY - Self-reported ethnicity (phv00482732.v1.p1)
- ETHNICITY - Self-reported ethnicity (phv00498141.v1.p1)
- RACE - Self-reported race (phv00482733.v1.p1)
- RACE - Self-reported race (phv00498142.v1.p1)
- RACE - Reported Race (phv00482728.v1.p1)
Other (73)
- ANALYTE_TYPE - Sample nucleic acid type (phv00302075.v1.p1)
- ANALYTE_TYPE - Analyte Type (phv00482759.v1.p1)
- ANALYTE_TYPE - The analyte type of the sample (phv00482767.v1.p1)
- ANALYTE_TYPE - Sample nucleic acid type (phv00482772.v1.p1)
- ANALYTE_TYPE - The analyte type of the sample (phv00498153.v1.p1)
- BIOPSY_SPECIMEN - The type of biopsy specimen (phv00482766.v1.p1)
- BIOPSY_SPECIMEN - The type of biopsy specimen (phv00498152.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00302076.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00482758.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00482768.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00482773.v1.p1)
- BODY_SITE - The collection site of the sample (phv00498154.v1.p1)
- CAPTURE_TYPE - Sequence library capture method (phv00302079.v1.p1)
- CENSORED - Progression status; whether or not an individual was censored (phv00482741.v1.p1)
- COHORT - Sequencing cohort (phv00302071.v1.p1)
- COMPOSITE_LYMPHOMA_STAGE - Composite lymphoma stage (phv00498146.v1.p1)
- CONSENT - Consent group (phv00302055.v2.p1)
- DIAGNOSIS - Clinical diagnosis (phv00482730.v1.p1)
- DLBCL_STAGE - Diffuse large B-cell lymphoma stage (phv00498144.v1.p1)
- EARLY_STAGE_DESIGNATION - GSHG Early Stage (phv00482735.v1.p1)
- EBV_ALIGNMENT_STATUS - Epstein Barr virus status determined by competitive alignment (phv00482743.v1.p1)
- EBV_EBER_STATUS - Epstein Barr virus status determined by EBER ISH (phv00482744.v1.p1)
- ECOG_PS - ECOG performance status score (phv00302069.v2.p1)
- ECOG_PS - ECOG performance status score (phv00482754.v1.p1)
- FL_STAGE - Follicular lymphoma stage (phv00498145.v1.p1)
- FLIPI - Follicular lymphoma international prognostic index (FLIPI) (phv00498149.v1.p1)
- FLIPI_SCORE - Prognostic index score (phv00302070.v2.p1)
- FLIPI_SCORE - Prognostic index score (phv00482755.v1.p1)
- GRADE_OF_BX_SEQ - Grade of biopsy sequenced (phv00302064.v1.p1)
- GRADE_OF_BX_SEQ - Grade of biopsy sequenced (phv00482749.v1.p1)
- HISTOLOGICAL_TYPE - Type of sample (phv00302074.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00482760.v1.p1)
- HISTOLOGICAL_TYPE - Type of sample (phv00482770.v1.p1)
- HL_STAGE - Hodgkin lymphoma stage (phv00498143.v1.p1)
- HODGKIN_SUB_TYPE - Sub-type of Hodgkin lymphoma (phv00482737.v1.p1)
- HRS_CELL_COUNT - Approximate count of Hodgkin and Reed/Sternberg cells (phv00482742.v1.p1)
- IPI - International prognostic index for diffuse large B-cell lymphoma (phv00498147.v1.p1)
- IPS - International Prognostic Score (phv00482736.v1.p1)
- IPS - International prognostic score for Hodgkin lymphoma (phv00498148.v1.p1)
- IS_TUMOR - Tumor status of the sample (phv00302077.v2.p1)
- IS_TUMOR - Tumor status (phv00482761.v1.p1)
- IS_TUMOR - The tumor status of the sample (phv00482765.v1.p1)
- IS_TUMOR - Tumor status of the sample (phv00482771.v1.p1)
- IS_TUMOR - The tumor status of the sample (phv00498151.v1.p1)
- LDH_ELEVATED - Is LDH elevated (phv00302067.v1.p1)
- LDH_ELEVATED - Is LDH elevated (phv00482752.v1.p1)
- NHL_TYPE - Non-Hodgkin lymphoma type (phv00302062.v1.p1)
- NHL_TYPE - Non-Hodgkin lymphoma type (phv00482747.v1.p1)
- NODAL_SITES - Number of involved nodal sites used in calculating the FLIPI score (PMID:15126323) (phv00302066.v2.p1)
- NODAL_SITES - Number of involved nodal sites used in calculating the FLIPI score (PMID:15126323) (phv00482751.v1.p1)
- PFS_PRIMARY - Progression free survival (primary samples) (phv00482739.v1.p1)
- PFS_RELAPSE - Progression free survival (relapse samples) (phv00482740.v1.p1)
- PRIMARY_RELAPSE - Contributed biopsy is diagnostic biopsy or relapse sample biopsy (phv00482734.v1.p1)
- SAMPLE_ID - Sample ID (phv00302072.v1.p1)
- SAMPLE_ID - De-identified Sample ID (phv00482757.v1.p1)
- SAMPLE_ID - De-identified Sample ID (phv00482764.v1.p1)
- SAMPLE_ID - Sample ID (phv00482769.v1.p1)
- SAMPLE_ID - De-identified Sample ID (phv00498150.v1.p1)
- SAMPLE_ID - Sample ID (phv00302058.v2.p1)
- SIMPLE_SAMPLE_NAME - Short descriptive sample name (phv00302073.v1.p1)
- STAGE - Lymphoma stage (phv00482738.v1.p1)
- STAGE - Lymphoma stage (phv00302065.v1.p1)
- STAGE - Lymphoma stage (phv00482750.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00482731.v1.p1)
- SUBJECT_ID - De-identified subject ID (phv00302060.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00482746.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00498140.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00482727.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00302054.v2.p1)
- SUBJECT_ID - De-identified subject ID (phv00302057.v2.p1)
- TIMEPOINT - Time on study (phv00482762.v1.p1)
- TISSUE_TYPE - Tissue treatment prior to DNA extraction (phv00302078.v1.p1)
- TUMOR_TREATMENT - Type of tumor treatment for sample (phv00482763.v1.p1)